-transparent.png){kind=logo}
GM-CSF was used to overcome fatal myelosuppression after cytotoxic chemotherapy. Two different application modalities were compared: a continuous 24 h infusion was more effective compared to a 30 min short term infusion. Using the former modality at a dose of 10 micrograms/kg/d for five days very impressive responses were observed. No major side effects did occur. The first 13 patients treated in this way included 8 AML cases. Only one of these latter patients had a leukemia relapse. However, in this patient the immediate GM-CSF response was clearly separated from the relapse occurring later in the observation period. Thus, the preliminary results of the present paper suggest that GM-CSF besides of being very efficient in accelerating granulocyte recovery does not stimulate the growth of AML blasts in vivo in patients with only minimal residual disease.
C Gattringer, and
J Thaler, and
J Drach, and
M Micksche, and
H Huber
October 1989,
Haematologica,
C Gattringer, and
J Thaler, and
J Drach, and
M Micksche, and
H Huber
August 1994,
Medizinische Klinik (Munich, Germany : 1983),
C Gattringer, and
J Thaler, and
J Drach, and
M Micksche, and
H Huber
July 1990,
Bone marrow transplantation,
C Gattringer, and
J Thaler, and
J Drach, and
M Micksche, and
H Huber
January 2003,
Developments in biologicals,
C Gattringer, and
J Thaler, and
J Drach, and
M Micksche, and
H Huber
December 2002,
Clinical immunology (Orlando, Fla.),
C Gattringer, and
J Thaler, and
J Drach, and
M Micksche, and
H Huber
August 1989,
Annals of internal medicine,
C Gattringer, and
J Thaler, and
J Drach, and
M Micksche, and
H Huber
September 2002,
Current opinion in investigational drugs (London, England : 2000),
C Gattringer, and
J Thaler, and
J Drach, and
M Micksche, and
H Huber
November 1989,
British journal of haematology,
C Gattringer, and
J Thaler, and
J Drach, and
M Micksche, and
H Huber
March 1994,
Acta dermato-venereologica,
C Gattringer, and
J Thaler, and
J Drach, and
M Micksche, and
H Huber
September 2002,
Thorax,
